ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2015
Identification and Characterization of Cefazolin-Induced Liver Injury.
Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- The incidence of chronic drug-induced liver injury: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Mixed hepatocellular-cholestatic liver injury from cefepime: A case report.World journal of clinical cases · 2026Article
- Intrahepatic diffuse periportal hyperintensity patterns on hepatobiliary phase of gadoxetate-enhanced MRI: a non-invasive imaging biomarker for clinical stratification of liver injury.Abdominal radiology (New York) · 2025Article
- Clinical and Genetic Associations in Cephalosporin-Induced Liver Injury: Insights From the Drug-Induced Liver Injury Network.Alimentary pharmacology & therapeutics · 2025Article
- Article
- Cephalosporin Allergy: Updates on Diagnostic Testing.Current allergy and asthma reports · 2024Review
- Article
- Article
- Liver Damage and microRNAs: An Update.Current issues in molecular biology · 2022Review
- Article
- Value of liver biopsy in the diagnosis of drug-induced liver injury.Journal of hepatology · 2022Article
- Safety and Effectiveness of High-Dose Cefazolin in Patients With High Body Weight: A Retrospective Cohort Study.Open forum infectious diseases · 2022Article
- A novel quantitative computer-assisted drug-induced liver injury causality assessment tool (DILI-CAT).PloS one · 2022Article
- Semimechanistic Modeling of the Effects of Blast Overpressure Exposure on Cefazolin Pharmacokinetics in Mice.The Journal of pharmacology and experimental therapeutics · 2021Article
- Signatures in drug-induced liver injury.Current opinion in gastroenterology · 2020Review
- Drug-Induced Liver Injury: Clinical and Etiologic Features at a Large Tertiary Teaching Hospital in China.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Fulminant Hepatic Failure in the Course of an Outpatient Anesthetic Procedure: Sevoflurane among Other High-Risk Factors.Case reports in anesthesiology · 2020Article
- Tools for causality assessment in drug-induced liver disease.Current opinion in gastroenterology · 2019Review
- Incidence, clinical features, and risk factors of fluoroquinolone-induced acute liver injury: a case-control study.Therapeutics and clinical risk management · 2019Article
- Cefazolin Induced Liver Injury and Hypoprothrombinemia.Journal of clinical and experimental hepatology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
BACKGROUND &
aimsCephalosporin antibiotics are popular because they have a broad spectrum of activity and are generally well tolerated; however, cephalosporin-induced liver injury is considered rare. We describe a new syndrome associated with a single intravenous dose of cefazolin and the clinical features of cephalosporin-induced liver injury.
methodsThe Drug-Induced Liver Injury (DILI) Network collected detailed clinical data on 1212 patients with DILI between 2004 and 2012. We analyzed data from 41 patients in whom cephalosporins were implicated as primary agents of liver disease; 33 formally were adjudicated as having cephalosporin-induced DILI.
resultsNineteen patients developed clinically apparent DILI after a single intravenous dose of cefazolin. All patients developed self-limited liver injury 3 to 23 days after receiving cefazolin during surgery-often during a minor outpatient procedure. The latency period was 20 days. Clinical features included itching, jaundice, nausea, fever, and rash. Laboratory abnormalities included a mixed or cholestatic pattern of serum enzyme increases. We identified 14 more patients with DILI attributed to other cephalosporins (5 first-generation, 2 second-generation, 6 third-generation, and 1 fourth-generation agent). Although latency and injury patterns were similar for cefazolin and other cephalosporins, the other cephalosporins were associated with more severe courses of injury, including 2 deaths from liver failure.
conclusionsDILI can develop after a single dose of cefazolin. It is characterized by a latency period of 1 to 3 weeks after exposure, a cholestatic biochemical pattern, and a self-limited moderate to severe clinical course. Other cephalosporins can cause a similar but more severe injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.